Charles River Laboratories International, Inc 8-K, filed Nov 4, 2026
Charles River Laboratories International, Inc. (CRL)
8-K
2026-11-04
For: 2026-11-04
View Original
Added on
November 04, 2026
About this 8-K
Charles River Laboratories International, Inc filed this 8-K on November 4, 2026.
Charles River Laboratories reported third-quarter revenue of $982.7 million, 4.7% organic growth, and non-GAAP diluted EPS of $3.09. It raised 2026 organic revenue guidance to at least +1.5% and non-GAAP EPS guidance to $11.35 – $11.55. AI summary
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s Telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02. Results of Operations and Financial Condition
On November 4, 2026, Charles River Laboratories International, Inc. issued a press release providing financial results for the third quarter ended September 26, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
The press release, attached as an exhibit to this report, includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press release are "forward-looking" rather than historic. The press release also states that these and other risks relating to Charles River are set forth in the documents filed by Charles River with the Securities and Exchange Commission.
ITEM 9.01. Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |||||||||||
| Date: | November 4, 2026 | By: | /s/ GLENN COLEMAN | ||||||||
Glenn Coleman Corporate Executive Vice President and Chief Financial Officer | |||||||||||
3
Exhibit 99.1
NEWS RELEASE
Charles River Laboratories Announces Third-Quarter 2026 Results
WILMINGTON, MA, November 4, 2026 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter ended September 26, 2026.
Key Highlights
•Reports third-quarter revenue of $982.7 million, GAAP earnings per share of $6.86, and non-GAAP earnings per share of $3.09.
•Organic revenue growth of 4.7%, outperforming the Company's prior outlook and representing a return to organic revenue growth for the second consecutive quarter.
•Operating margin increased year-over-year, with non-GAAP operating margin increasing 330 basis points to 23.0% and GAAP operating margin increasing 730 basis points to 20.6%.
•Non-GAAP earnings per share increased 27.2% year-over-year.
•Increases 2026 guidance for revenue and non-GAAP earnings per share.
•Organic revenue guidance increasing by 100 basis points and non-GAAP earnings per share guidance increasing by $0.15 at midpoint.
•Guidance increases primarily driven by third-quarter outperformance, led by a better-than-expected performance in the DSA segment and a lower tax rate.
•Charles River unveiled its Pathway to Purpose strategic vision and Create the FutureTM initiative at its 2026 Investor Day, outlining initiatives designed to enhance operational excellence, strengthen scientific leadership, and drive long-term value creation.
•The Company advanced modernization efforts through the implementation of its Endosafe® Cartridge Technology Automated Manufacturing Suite, which utilizes a fully automated production suite to increase production capacity and strengthen manufacturing controls and digital traceability. In addition, the Company partnered with Autolomous to launch Apollo OrchestrateTM, a new capability within Charles River's Apollo® platform to digitize and transform laboratory workflows, increase efficiency, and provide greater transparency and connectivity with clients.
•Charles River has also taken steps to continue to strengthen its scientific capabilities. It recently announced an industry collaboration with the U.S. Food and Drug Administration (FDA) to validate preclinical screening tools to quantify and rank the abuse potential of new drugs.
•To further advance its Alternative Methods Advancement ProjectTM (AMAPTM) initiative, the Company introduced a new, rapid cell banking program designed to significantly accelerate product release timelines in its Biologics Testing Solutions business by incorporating in vitro next-generation sequencing capabilities into the cell bank production process. In addition, its Virtual Control Group (VCG) database and methodology will be
1
Exhibit 99.1
used in an upcoming Good Laboratory Practice (GLP)-compliant safety assessment study for Ipsen.
Third-Quarter Results
Revenue was $982.7 million, a decrease of 2.2% from $1,004.9 million in the third quarter of 2025, primarily driven by the impact of the May 2026 divestitures. On an organic basis, revenue increased 4.7%, driven by revenue growth in the Manufacturing Solutions (Manufacturing) and Discovery and Safety Assessment (DSA) segments. Organic revenue growth excludes the effect of acquisitions, divestitures, and foreign currency translation.
In the third quarter of 2026, the GAAP operating margin was 20.6%, compared to 13.3% in the third quarter of 2025, driven primarily by a benefit of $44.6 million in the DSA segment from the reversal of acquired non-income tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction. The GAAP net income available to common shareholders for the third quarter of 2026 was $333.1 million, or $6.86 per diluted share, compared to GAAP net income of $54.4 million, or $1.10 per diluted share for the same period in 2025. The GAAP net income and earnings per share increases included a benefit totaling $245.6 million, or $5.06 per share, associated with the reversal of acquired tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction.
On a non-GAAP basis, the third-quarter operating margin increased to 23.0% from 19.7% in the third quarter of 2025, primarily as a result of the benefit of the CDMO divestiture and operating leverage from higher sales volume for safety assessment services. Non-GAAP net income was $150.1 million for the third quarter of 2026, an increase of 24.8% from $120.3 million for the same period in 2025. Third-quarter diluted earnings per share on a non-GAAP basis were $3.09, an increase of 27.2% from $2.43 per share in the third quarter of 2025. The non-GAAP net income and earnings per share increases were driven primarily by the higher operating margin and a lower tax rate.
Birgit Girshick, Chief Executive Officer, said, “In the third quarter, we were encouraged by the continued strength of the biopharmaceutical demand environment and that was reflected in our financial results. Revenue and earnings per share outperformed our prior expectations, DSA net bookings and proposals continued to show robust, year-over-year increases, and we continued to make meaningful progress towards our strategy and long-term financial targets. We see significant opportunities to continue to strengthen Charles River’s position as a leading scientific partner for regulated testing across the drug development continuum. Through our Pathway to Purpose strategy, we are building a more agile, client-centric organization that will deepen client relationships, expand engagement across our portfolio, and increase our share of R&D spend as demand trends continue to improve."
Third-Quarter Segment Results
Discovery and Safety Assessment (DSA)
Revenue for the DSA segment was $596.3 million in the third quarter of 2026, a decrease of 0.7% from $600.7 million in the third quarter of 2025, primarily driven by the divestiture of
2
Exhibit 99.1
certain European Discovery Services sites. Organic revenue increased by 5.9%, driven primarily by higher study volume for regulated safety assessment services.
In the third quarter of 2026, the DSA segment’s GAAP operating margin increased to 28.9% from 20.5% in the third quarter of 2025. The increase was primarily driven by the reversal of acquired non-income tax reserves. On a non-GAAP basis, the operating margin increased to 26.8% from 25.4% in the third quarter of 2025. The non-GAAP operating margin increase was primarily driven by operating leverage from higher study volume for regulated safety assessment services, as well as lower sourcing costs for large research models.
Manufacturing Solutions (Manufacturing)
Revenue for the Manufacturing segment was $178.9 million in the third quarter of 2026, a decrease of 6.2% from $190.7 million in the third quarter of 2025, primarily driven by the CDMO divestiture. Organic revenue increased 7.4%, driven by strong demand in both the Biologics Testing Solutions and Microbial Solutions businesses.
The Manufacturing segment’s GAAP operating margin was 35.7%, compared to 20.9% in the third quarter of 2025. On a non-GAAP basis, the operating margin increased to 38.6% from 26.7% in the third quarter of 2025. The GAAP and non-GAAP increases were driven primarily by the benefit of the CDMO divestiture.
Research Models and Services (RMS)
Revenue for the RMS segment was $207.5 million in the third quarter of 2026, a decrease of 2.8% from $213.5 million in the third quarter of 2025, primarily driven by the Cell Solutions divestiture. Organic revenue decreased by 0.6%, due primarily to lower revenue for small research models in North America and for large research models. The decline was partially offset by higher revenue for small research models in China and for research model services, particularly the Insourcing Solutions business.
In the third quarter of 2026, the RMS segment’s GAAP operating margin increased to 19.9% from 16.2% in the third quarter of 2025, primarily due to lower costs related to the Cell Solutions divestiture and restructuring initiatives. On a non-GAAP basis, the operating margin decreased to 24.4% from 25.0%. The non-GAAP operating margin decrease was primarily driven by the impact of an unfavorable revenue mix, both geographically and related to large research models.
2026 Guidance Update
The Company is increasing its 2026 revenue and earnings per share guidance, which was last updated on August 5, 2026. This increase primarily reflects the third-quarter outperformance, which was principally driven by the better-than-expected performance in the DSA segment and a lower tax rate. On a GAAP basis, the Company is also increasing its earnings per share guidance, due primarily to the third-quarter benefit associated with the reversal of acquired tax reserves.
3
Exhibit 99.1
The Company’s 2026 guidance for revenue and earnings per share is as follows:
| 2026 GUIDANCE | CURRENT | PRIOR | ||||||
| Revenue growth/(decrease), reported | (2.0)% - (1.5)% | (3.5)% - (2.5)% | ||||||
| Less: Contribution from acquisitions | 0.0% - (0.5)% | 0.0% - (0.5)% | ||||||
Add: Impact from divestitures | ~4.5% | ~4.5% | ||||||
| Less: Favorable impact of foreign exchange | (0.5)% - (1.0)% | (0.5)% - (1.0)% | ||||||
Revenue growth/(decrease), organic (1) | At least +1.5% | 0.0% - 1.0% | ||||||
| GAAP EPS estimate | $8.15 – $8.35 | $3.05 – $3.35 | ||||||
| Acquisition-related amortization (2) | ~$2.10 | ~$2.30 | ||||||
| Acquisition- and divestiture-related costs (3) | ~$4.70 | ~$4.75 | ||||||
| Reversal of acquired tax reserves (4) | ($5.03) | -- | ||||||
| Costs associated with restructuring and efficiency initiatives (5) | ~$1.50 | ~$1.20 | ||||||
| Other, net (6) | ($0.03) | ($0.17) | ||||||
| Non-GAAP EPS estimate | $11.35 – $11.55 | $11.15 – $11.45 | ||||||
Footnotes to Guidance Table:
(1) Organic revenue growth is defined as reported revenue growth adjusted for completed acquisitions and divestitures (including the CDMO and Cell Solutions businesses, as well as certain European Discovery Services sites), as well as foreign currency translation.
(2) These adjustments primarily include amortization related to intangible assets, as well as the purchase accounting step-up on inventory and certain long-term biological assets.
(3) These adjustments include costs related to the evaluation and integration of acquisitions and divestitures, as well as a net loss on divestitures and other transaction-related tax adjustments.
(4) This adjustment is related to the third-quarter benefit associated with the reversal of acquired tax reserves following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction.
(5) These adjustments primarily include site consolidation (including site transition costs), severance, impairment, third-party consulting and professional services, and other costs related to the Company’s restructuring actions and efficiency initiatives. These adjustments also include gains and/or losses on the sale of certain assets and real estate.
(6) These adjustments primarily include: (i) certain venture capital and other strategic investment losses/(gains), net. This item only includes recognized gains or losses on certain investments. The Company does not forecast the future performance of these investments; and (ii) reductions to a previous $27 million inventory charge associated with a non-human primate (NHP) supply matter. As a result of the resolution of the U.S. government investigations during fiscal year 2025, certain NHPs were subsequently utilized.
Webcast
Charles River has scheduled a live webcast on Wednesday, November 4, 2026, at 9:00 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.
4
Exhibit 99.1
Non-GAAP Reconciliations
The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, and non-GAAP net income. Non-GAAP financial measures exclude, but are not limited to, the amortization of intangible assets and the purchase accounting step-up adjustment on inventory and certain long term biological assets, and other charges and adjustments related to our acquisitions and divestitures, including expenses associated with evaluating and integrating acquisitions and divestitures, including advisory fees, certain transition costs, and certain other transaction-related costs, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest, including the divestitures of our CDMO and Cell Solutions businesses, the sale of certain of our European Discovery Services sites, and the sale of certain assets including real estate; severance and other costs associated with our restructuring initiatives; investment gains or losses associated with our venture capital and certain other strategic equity investments; certain legal costs and adjustments related to an NHP inventory charge in our DSA segment related to now concluded U.S. government investigations into the NHP supply chain; legal and advisory costs related to entering into a Cooperation Agreement with a shareholder; tax effect of all of the aforementioned matters; and adjustments related to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge, the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure, the revaluation of deferred tax liabilities as a result of foreign tax legislation, and the tax benefit recognized as a result of the changes in tax law enacted in a foreign jurisdiction. This press release also refers to our revenue on both a GAAP and non-GAAP basis: on a non-GAAP basis, we define “organic revenue growth” as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition.
5
Exhibit 99.1
Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company’s website at ir.criver.com.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding: the projected and/or anticipated future financial performance of Charles River and our specific businesses, including as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, interest rates, and enhanced efficiency initiatives, including our Create the Future initiative; our expectations with respect to our ability to gain market share; our ability to create long-term value for our shareholders and successfully execute on our strategic initiatives, including our Pathway to Purpose strategic vision, and the impact and results of such initiatives; the Company’s plans or prospects, expectations and long-term goals associated with our business; earnings per share; operating margin; client demand, particularly the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to booking trends and the impacts thereof; our expectations with respect to pricing of our products and services; our expectations with respect to future tax rates and the impact of such tax rates on our business; our expectations with respect to the impact of acquisitions and divestitures, including the acquisition of the assets of K.F. (Cambodia) Ltd. and of PathoQuest SAS, the divestitures of the Company's CDMO and Cell Solutions businesses, the sale of certain of our European Discovery Services sites, and the sale of certain assets including real estate; our service offerings, client perception, strategic relationships, revenue, revenue growth rates, revenue growth drivers, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and identification of spending trends by our clients and funding available to them; ability to gain market share and capitalize on business and growth opportunities; the impact of our restructuring initiatives, including annualized savings; and the impact of our stock repurchase authorization. Forward-looking statements are based on Charles River’s current expectations and beliefs, speak only as of the date of this press release, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the impact of NHP supply constraints; changes and uncertainties in the global economy and financial markets, including
6
Exhibit 99.1
disruptions in the global economy caused by geopolitical conflicts; the ability to successfully integrate businesses we acquire, and risks and uncertainties associated with businesses that we acquire; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; demand and booking trends; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; the impact of unauthorized access into our information systems; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 18, 2026, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River. Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
# # #
Investor Contact: Media Contact:
Todd Spencer Amy Cianciaruso
Corporate Vice President, Corporate Senior Vice President,
Investor Relations Chief Communications Officer
781.222.6455 781.222.6168
todd.spencer@crl.com amy.cianciaruso@crl.com
7
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||||||||||||||||||||
| SCHEDULE 1 | ||||||||||||||||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) | ||||||||||||||||||||||||||||||||
| (in thousands, except for per share data) | ||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||||||||||||||||||
| Service revenue | $ | 780,341 | $ | 808,042 | $ | 2,386,780 | $ | 2,446,801 | ||||||||||||||||||||||||
| Product revenue | 202,391 | 196,810 | 595,860 | 574,354 | ||||||||||||||||||||||||||||
| Total revenue | 982,732 | 1,004,852 | 2,982,640 | 3,021,155 | ||||||||||||||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||||||||
| Cost of services provided (excluding amortization of intangible assets) | 522,836 | 572,635 | 1,683,750 | 1,734,939 | ||||||||||||||||||||||||||||
| Cost of products sold (excluding amortization of intangible assets) | 102,026 | 93,425 | 282,982 | 272,625 | ||||||||||||||||||||||||||||
| Selling, general and administrative | 140,591 | 177,589 | 528,910 | 546,937 | ||||||||||||||||||||||||||||
| Amortization of intangible assets | 14,641 | 27,404 | 44,575 | 158,052 | ||||||||||||||||||||||||||||
| Operating income | 202,638 | 133,799 | 442,423 | 308,602 | ||||||||||||||||||||||||||||
| Other income (expense): | ||||||||||||||||||||||||||||||||
| Interest income | 958 | 1,422 | 3,023 | 3,923 | ||||||||||||||||||||||||||||
| Interest expense | (28,525) | (25,403) | (85,607) | (83,254) | ||||||||||||||||||||||||||||
| Other expense, net | (4,414) | (22,618) | (165,954) | (34,675) | ||||||||||||||||||||||||||||
| Income before income taxes | 170,657 | 87,200 | 193,885 | 194,596 | ||||||||||||||||||||||||||||
| Provision (benefit) for income taxes | (163,787) | 31,644 | (124,997) | 60,469 | ||||||||||||||||||||||||||||
| Net income | 334,444 | 55,556 | 318,882 | 134,127 | ||||||||||||||||||||||||||||
| Less: Net income attributable to noncontrolling interests | 1,377 | 1,134 | 2,140 | 1,910 | ||||||||||||||||||||||||||||
| Net income attributable to common shareholders | $ | 333,067 | $ | 54,422 | $ | 316,742 | $ | 132,217 | ||||||||||||||||||||||||
| Earnings per common share | ||||||||||||||||||||||||||||||||
| Basic | $ | 6.97 | $ | 1.11 | $ | 6.56 | $ | 2.66 | ||||||||||||||||||||||||
| Diluted | $ | 6.86 | $ | 1.10 | $ | 6.48 | $ | 2.65 | ||||||||||||||||||||||||
| Weighted-average number of common shares outstanding | ||||||||||||||||||||||||||||||||
| Basic | 47,803 | 49,213 | 48,258 | 49,680 | ||||||||||||||||||||||||||||
| Diluted | 48,584 | 49,426 | 48,899 | 49,866 | ||||||||||||||||||||||||||||
8
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||
| SCHEDULE 2 | ||||||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||
| September 26, 2026 | December 27, 2025 | |||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 200,381 | $ | 213,770 | ||||||||||
| Trade receivables and contract assets, net of allowances for credit losses of $10,511 and $10,463, respectively | 735,305 | 708,856 | ||||||||||||
| Inventories | 319,638 | 299,103 | ||||||||||||
| Prepaid assets | 97,265 | 96,108 | ||||||||||||
| Other current assets | 182,439 | 129,212 | ||||||||||||
| Total current assets | 1,535,028 | 1,447,049 | ||||||||||||
| Property, plant and equipment, net | 1,497,335 | 1,655,219 | ||||||||||||
| Venture capital and strategic equity investments | 194,521 | 206,972 | ||||||||||||
| Operating lease right-of-use assets, net | 332,330 | 361,415 | ||||||||||||
| Goodwill | 3,084,112 | 2,764,253 | ||||||||||||
| Intangible assets, net | 238,662 | 339,995 | ||||||||||||
| Deferred tax assets | 67,467 | 67,334 | ||||||||||||
| Other assets | 502,052 | 293,185 | ||||||||||||
| Total assets | $ | 7,451,507 | $ | 7,135,422 | ||||||||||
| Liabilities, Redeemable Noncontrolling Interests and Equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 144,507 | $ | 148,800 | ||||||||||
| Accrued compensation | 225,937 | 268,854 | ||||||||||||
| Deferred revenue | 204,204 | 210,418 | ||||||||||||
| Accrued liabilities | 285,737 | 270,085 | ||||||||||||
| Other current liabilities | 228,873 | 222,158 | ||||||||||||
| Total current liabilities | 1,089,258 | 1,120,315 | ||||||||||||
| Long-term debt, net and finance leases | 2,443,461 | 2,136,360 | ||||||||||||
| Operating lease right-of-use liabilities | 405,351 | 434,048 | ||||||||||||
| Deferred tax liabilities | 81,815 | 95,203 | ||||||||||||
| Other long-term liabilities | 156,356 | 138,302 | ||||||||||||
| Total liabilities | 4,176,241 | 3,924,228 | ||||||||||||
| Redeemable noncontrolling interests | 43,173 | 41,263 | ||||||||||||
| Equity: | ||||||||||||||
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | — | — | ||||||||||||
Common stock, $0.01 par value; 120,000 shares authorized; 49,699 shares issued and 47,876 shares outstanding as of September 26, 2026, and 49,217 shares issued and outstanding as of December 27, 2025 | 497 | 492 | ||||||||||||
| Additional paid-in capital | 2,035,124 | 1,947,301 | ||||||||||||
| Retained earnings | 1,705,362 | 1,388,620 | ||||||||||||
Treasury stock, at cost, 1,823 and zero shares, as of September 26, 2026 and December 27, 2025, respectively | (323,281) | — | ||||||||||||
| Accumulated other comprehensive loss | (190,691) | (171,783) | ||||||||||||
| Total Charles River Laboratories International, Inc. equity | 3,227,011 | 3,164,630 | ||||||||||||
| Nonredeemable noncontrolling interest | 5,082 | 5,301 | ||||||||||||
| Total equity | 3,232,093 | 3,169,931 | ||||||||||||
| Total liabilities, redeemable noncontrolling interests and equity | $ | 7,451,507 | $ | 7,135,422 | ||||||||||
9
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||
| SCHEDULE 3 | ||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||||||||||
| (in thousands) | ||||||||||||||
| Nine Months Ended | ||||||||||||||
| September 26, 2026 | September 27, 2025 | |||||||||||||
| Cash flows relating to operating activities | ||||||||||||||
| Net income | $ | 318,882 | $ | 134,127 | ||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||||
| Depreciation and amortization | 206,701 | 325,035 | ||||||||||||
| Long-lived asset impairments | 27,171 | 36,185 | ||||||||||||
| Stock-based compensation | 62,929 | 53,451 | ||||||||||||
| Deferred income taxes | (4,089) | (15,122) | ||||||||||||
| Reversal of an unrecognized tax benefit reserve and related interest and penalties | (245,638) | — | ||||||||||||
| Write down of inventories | 4,033 | 10,697 | ||||||||||||
| (Gains) losses and impairments on venture capital and strategic equity investments, net | (4,897) | 33,955 | ||||||||||||
| (Gain) loss on sale of assets | (37,776) | 982 | ||||||||||||
| Provision for credit losses | 1,935 | 4,559 | ||||||||||||
| (Gain) loss on divestitures, net | 180,300 | (3,376) | ||||||||||||
| Other, net | (8,538) | 2,324 | ||||||||||||
| Changes in assets and liabilities: | ||||||||||||||
| Trade receivables and contract assets, net | (110,271) | 8,106 | ||||||||||||
| Inventories | 64,440 | (45,280) | ||||||||||||
| Accounts payable | 25,601 | 40,747 | ||||||||||||
| Accrued compensation | (26,898) | 81,870 | ||||||||||||
| Deferred revenue | 6,227 | (12,319) | ||||||||||||
| Customer contract deposits | 12,681 | (533) | ||||||||||||
| Other assets and liabilities, net | 2,094 | (65,282) | ||||||||||||
| Net cash provided by operating activities | 474,887 | 590,126 | ||||||||||||
| Cash flows relating to investing activities | ||||||||||||||
| Acquisition of businesses and assets, net of cash acquired | (467,254) | — | ||||||||||||
| Capital expenditures | (133,823) | (130,202) | ||||||||||||
| Purchases of investments and contributions to venture capital investments | (14,718) | (12,544) | ||||||||||||
| Proceeds from sale of investments | 18,876 | 5,637 | ||||||||||||
| Proceeds from surrender of life insurance policies | 58,127 | — | ||||||||||||
| Proceeds from sale of businesses and assets, net | 176,563 | 17,441 | ||||||||||||
| Other, net | (7,292) | 3,154 | ||||||||||||
| Net cash used in investing activities | (369,521) | (116,514) | ||||||||||||
| Cash flows relating to financing activities | ||||||||||||||
| Proceeds from long-term debt and revolving credit facility | 1,420,223 | 1,070,861 | ||||||||||||
| Payments on long-term debt, revolving credit facility, and finance lease obligations | (1,081,266) | (1,141,500) | ||||||||||||
| Proceeds from exercises of stock options | 29,733 | 3 | ||||||||||||
| Purchase of treasury stock | (324,105) | (360,577) | ||||||||||||
| Payment of contingent consideration and deferred acquisition consideration | (111,394) | (21,822) | ||||||||||||
| Purchase of remaining equity interests of other redeemable noncontrolling interest | — | (19,140) | ||||||||||||
| Other, net | (4,274) | (12,687) | ||||||||||||
| Net cash used in financing activities | (71,083) | (484,862) | ||||||||||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (1,199) | 14,900 | ||||||||||||
| Net change in cash, cash equivalents, and restricted cash | 33,084 | 3,650 | ||||||||||||
| Cash, cash equivalents, and restricted cash, beginning of period | 215,997 | 205,570 | ||||||||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 249,081 | $ | 209,220 | ||||||||||
10
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||||||||||||||||||||||||||
| SCHEDULE 4 | ||||||||||||||||||||||||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP | ||||||||||||||||||||||||||||||||||||||
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) | ||||||||||||||||||||||||||||||||||||||
| (in thousands, except percentages) | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||||||||
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||||||||||||||||||||||||
| Discovery and Safety Assessment | ||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 596,322 | $ | 600,685 | $ | 1,799,752 | $ | 1,811,323 | ||||||||||||||||||||||||||||||
| Operating income | 172,376 | 123,153 | 400,650 | 339,886 | ||||||||||||||||||||||||||||||||||
| Operating income as a % of revenue | 28.9 | % | 20.5 | % | 22.3 | % | 18.8 | % | ||||||||||||||||||||||||||||||
| Add back: | ||||||||||||||||||||||||||||||||||||||
| Amortization related to acquisitions | 22,388 | 19,198 | 57,671 | 55,581 | ||||||||||||||||||||||||||||||||||
Acquisition, integration, and divestiture-related adjustments (2) | (43,603) | 2,407 | (35,368) | 4,755 | ||||||||||||||||||||||||||||||||||
| Severance | 4,487 | (148) | 8,193 | 5,068 | ||||||||||||||||||||||||||||||||||
| Asset impairment | — | 693 | 3,261 | 22,390 | ||||||||||||||||||||||||||||||||||
Cost savings and efficiency initiatives (3) | 5,173 | 3,985 | 13,952 | 10,690 | ||||||||||||||||||||||||||||||||||
Third-party legal and advisory costs and certain related items (4) | (1,272) | 3,242 | (8,414) | 25,029 | ||||||||||||||||||||||||||||||||||
| Total non-GAAP adjustments to operating income | $ | (12,827) | $ | 29,377 | $ | 39,295 | $ | 123,513 | ||||||||||||||||||||||||||||||
| Operating income, excluding non-GAAP adjustments | $ | 159,549 | $ | 152,530 | $ | 439,945 | $ | 463,399 | ||||||||||||||||||||||||||||||
| Non-GAAP operating income as a % of revenue | 26.8 | % | 25.4 | % | 24.4 | % | 25.6 | % | ||||||||||||||||||||||||||||||
| Depreciation and amortization | $ | 45,281 | $ | 44,001 | $ | 126,828 | $ | 128,660 | ||||||||||||||||||||||||||||||
| Capital expenditures | $ | 30,048 | $ | 25,709 | $ | 87,990 | $ | 78,730 | ||||||||||||||||||||||||||||||
| Manufacturing Solutions | ||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 178,878 | $ | 190,693 | $ | 557,514 | $ | 570,014 | ||||||||||||||||||||||||||||||
| Operating income | 63,835 | 39,926 | 176,280 | 43,367 | ||||||||||||||||||||||||||||||||||
| Operating income as a % of revenue | 35.7 | % | 20.9 | % | 31.6 | % | 7.6 | % | ||||||||||||||||||||||||||||||
| Add back: | ||||||||||||||||||||||||||||||||||||||
Amortization related to acquisitions (5) | 2,145 | 8,265 | 6,151 | 100,675 | ||||||||||||||||||||||||||||||||||
Acquisition, integration, and divestiture-related adjustments (2) | 1,431 | — | 4,195 | — | ||||||||||||||||||||||||||||||||||
| Severance | 1,348 | 1,281 | 806 | 3,102 | ||||||||||||||||||||||||||||||||||
| Asset impairment | 316 | 91 | 567 | 6,449 | ||||||||||||||||||||||||||||||||||
Cost savings and efficiency initiatives (3) | — | 1,263 | 1,511 | 4,239 | ||||||||||||||||||||||||||||||||||
| Total non-GAAP adjustments to operating income | $ | 5,240 | $ | 10,900 | $ | 13,230 | $ | 114,465 | ||||||||||||||||||||||||||||||
| Operating income, excluding non-GAAP adjustments | $ | 69,075 | $ | 50,826 | $ | 189,510 | $ | 157,832 | ||||||||||||||||||||||||||||||
| Non-GAAP operating income as a % of revenue | 38.6 | % | 26.7 | % | 34.0 | % | 27.7 | % | ||||||||||||||||||||||||||||||
| Depreciation and amortization | $ | 7,784 | $ | 17,377 | $ | 23,572 | $ | 127,343 | ||||||||||||||||||||||||||||||
| Capital expenditures | $ | 6,839 | $ | 5,191 | $ | 18,747 | $ | 33,631 | ||||||||||||||||||||||||||||||
| Research Models and Services | ||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 207,532 | $ | 213,474 | $ | 625,374 | $ | 639,818 | ||||||||||||||||||||||||||||||
| Operating income | 41,240 | 34,553 | 127,290 | 113,944 | ||||||||||||||||||||||||||||||||||
| Operating income as a % of revenue | 19.9 | % | 16.2 | % | 20.4 | % | 17.8 | % | ||||||||||||||||||||||||||||||
| Add back: | ||||||||||||||||||||||||||||||||||||||
| Amortization related to acquisitions | 7,063 | 12,905 | 21,601 | 36,266 | ||||||||||||||||||||||||||||||||||
Acquisition, integration, and divestiture-related adjustments (2) | — | — | 67 | 14 | ||||||||||||||||||||||||||||||||||
| Severance | 817 | 136 | 1,453 | 3,664 | ||||||||||||||||||||||||||||||||||
| Asset impairment | — | 4,635 | 22,031 | 7,458 | ||||||||||||||||||||||||||||||||||
Cost savings and efficiency initiatives (3) | 1,598 | 1,053 | (18,935) | 3,545 | ||||||||||||||||||||||||||||||||||
| Total non-GAAP adjustments to operating income | $ | 9,478 | $ | 18,729 | $ | 26,217 | $ | 50,947 | ||||||||||||||||||||||||||||||
| Operating income, excluding non-GAAP adjustments | $ | 50,718 | $ | 53,282 | $ | 153,507 | $ | 164,891 | ||||||||||||||||||||||||||||||
| Non-GAAP operating income as a % of revenue | 24.4 | % | 25.0 | % | 24.5 | % | 25.8 | % | ||||||||||||||||||||||||||||||
| Depreciation and amortization | $ | 16,145 | $ | 21,939 | $ | 48,018 | $ | 63,410 | ||||||||||||||||||||||||||||||
| Capital expenditures | $ | 9,411 | $ | 3,173 | $ | 25,968 | $ | 14,099 | ||||||||||||||||||||||||||||||
| Unallocated Corporate Overhead | $ | (74,813) | $ | (63,833) | $ | (261,797) | $ | (188,595) | ||||||||||||||||||||||||||||||
| Add back: | ||||||||||||||||||||||||||||||||||||||
Acquisition, integration, and divestiture-related adjustments (2) | 10,258 | 772 | 45,020 | 3,663 | ||||||||||||||||||||||||||||||||||
| Severance | 2,467 | 3,527 | 7,138 | 5,103 | ||||||||||||||||||||||||||||||||||
| Asset impairment | 422 | — | 965 | 184 | ||||||||||||||||||||||||||||||||||
Cost savings and efficiency initiatives (3) | 8,106 | 767 | 19,803 | 1,436 | ||||||||||||||||||||||||||||||||||
Third-party legal and advisory costs (4) | — | (146) | — | 6,230 | ||||||||||||||||||||||||||||||||||
| Total non-GAAP adjustments to operating expense | $ | 21,253 | $ | 4,920 | $ | 72,926 | $ | 16,616 | ||||||||||||||||||||||||||||||
| Unallocated corporate overhead, excluding non-GAAP adjustments | $ | (53,560) | $ | (58,913) | $ | (188,871) | $ | (171,979) | ||||||||||||||||||||||||||||||
| Total | ||||||||||||||||||||||||||||||||||||||
| Revenue | $ | 982,732 | $ | 1,004,852 | $ | 2,982,640 | $ | 3,021,155 | ||||||||||||||||||||||||||||||
| Operating income | 202,638 | 133,799 | 442,423 | 308,602 | ||||||||||||||||||||||||||||||||||
| Operating income as a % of revenue | 20.6 | % | 13.3 | % | 14.8 | % | 10.2 | % | ||||||||||||||||||||||||||||||
| Add back: | ||||||||||||||||||||||||||||||||||||||
Amortization related to acquisitions (5) | 31,596 | 40,368 | 85,423 | 192,522 | ||||||||||||||||||||||||||||||||||
Acquisition, integration, and divestiture-related adjustments (2) | (31,914) | 3,179 | 13,914 | 8,432 | ||||||||||||||||||||||||||||||||||
| Severance | 9,119 | 4,796 | 17,590 | 16,937 | ||||||||||||||||||||||||||||||||||
| Asset impairment | 738 | 5,419 | 26,824 | 36,481 | ||||||||||||||||||||||||||||||||||
Cost savings and efficiency initiatives (3) | 14,877 | 7,068 | 16,331 | 19,910 | ||||||||||||||||||||||||||||||||||
Third-party legal and advisory costs and certain related items (4) | (1,272) | 3,096 | (8,414) | 31,259 | ||||||||||||||||||||||||||||||||||
| Total non-GAAP adjustments to operating income | $ | 23,144 | $ | 63,926 | $ | 151,668 | $ | 305,541 | ||||||||||||||||||||||||||||||
| Operating income, excluding non-GAAP adjustments | $ | 225,782 | $ | 197,725 | $ | 594,091 | $ | 614,143 | ||||||||||||||||||||||||||||||
| Non-GAAP operating income as a % of revenue | 23.0 | % | 19.7 | % | 19.9 | % | 20.3 | % | ||||||||||||||||||||||||||||||
| Depreciation and amortization | $ | 72,260 | $ | 85,164 | $ | 206,701 | $ | 325,035 | ||||||||||||||||||||||||||||||
| Capital expenditures | $ | 46,810 | $ | 35,580 | $ | 133,823 | $ | 130,202 | ||||||||||||||||||||||||||||||
(1) | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | |||||||||||||||||||||||||||||||||||||
(2) | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. For the three and nine months ended September 26, 2026, this amount includes a $44.6 million tax benefit resulting from newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction within the Discovery and Safety Assessment reportable segment. | |||||||||||||||||||||||||||||||||||||
(3) | Cost savings and efficiency initiatives in 2026 primarily include site consolidation charges related to recent site optimization activities, cost of professional services related to certain improvement initiatives, and a pre-tax gain of $38.5 million in connection with the sale of certain assets in Wilmington, Massachusetts. The gain was recognized within the RMS reportable segment and unallocated corporate for $23.2 million and $15.3 million, respectively. | |||||||||||||||||||||||||||||||||||||
(4) | Within the DSA business, third‑party legal and advisory costs incurred during fiscal 2025 relate to U.S. government investigations into the NHP supply chain, which were concluded in fiscal 2025. Also included within DSA results for fiscal 2026 is the utilization of previously written‑down NHP inventory, resulting in partial reversals of the $27 million inventory charge recorded in fiscal 2024 following the resolution of the matter in fiscal 2025. Within Unallocated Corporate, third-party legal and advisory costs incurred during fiscal 2025 are associated with the execution of the Cooperation Agreement with a shareholder. | |||||||||||||||||||||||||||||||||||||
(5) | Amortization related to acquisitions for the nine months ended September 27, 2025 includes $71.0 million of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions reportable segment. | |||||||||||||||||||||||||||||||||||||
11
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ||||||||||||||||||||||||||||||||
| SCHEDULE 5 | ||||||||||||||||||||||||||||||||
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)(1) | ||||||||||||||||||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| September 26, 2026 | September 27, 2025 | September 26, 2026 | September 27, 2025 | |||||||||||||||||||||||||||||
| Net income available to Charles River Laboratories International, Inc. common shareholders | $ | 333,067 | $ | 54,422 | $ | 316,742 | $ | 132,217 | ||||||||||||||||||||||||
| Add back: | ||||||||||||||||||||||||||||||||
Non-GAAP adjustments to operating income (2) | 22,123 | 62,632 | 148,586 | 302,104 | ||||||||||||||||||||||||||||
| Venture capital and strategic equity investment losses and impairments, net | 2,231 | 20,201 | (4,636) | 31,594 | ||||||||||||||||||||||||||||
(Gain) loss on divestitures (3) | 461 | — | 180,687 | (3,376) | ||||||||||||||||||||||||||||
Accretion of deferred acquisition consideration (4) | 1,081 | — | 2,741 | — | ||||||||||||||||||||||||||||
| Tax effect of non-GAAP adjustments: | ||||||||||||||||||||||||||||||||
| Enacted tax law changes | — | 3,236 | — | 3,236 | ||||||||||||||||||||||||||||
| Tax impact of divestitures | — | — | (35,652) | — | ||||||||||||||||||||||||||||
| Interest on acquired uncertain tax positions | — | — | 11,271 | — | ||||||||||||||||||||||||||||
Reversal of an unrecognized tax benefit reserve and related interest and penalties (5) | (201,057) | — | (201,057) | — | ||||||||||||||||||||||||||||
| Tax effect of the remaining non-GAAP adjustments | (7,778) | (20,148) | (20,620) | (72,330) | ||||||||||||||||||||||||||||
| Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments | $ | 150,128 | $ | 120,343 | $ | 398,062 | $ | 393,445 | ||||||||||||||||||||||||
| Weighted average shares outstanding - Basic | 47,803 | 49,213 | 48,258 | 49,680 | ||||||||||||||||||||||||||||
| Effect of dilutive securities: | ||||||||||||||||||||||||||||||||
| Stock options, restricted stock units and performance share units | 781 | 213 | 641 | 186 | ||||||||||||||||||||||||||||
| Weighted average shares outstanding - Diluted | 48,584 | 49,426 | 48,899 | 49,866 | ||||||||||||||||||||||||||||
| Earnings per share attributable to common shareholders: | ||||||||||||||||||||||||||||||||
| Basic | $ | 6.97 | $ | 1.11 | $ | 6.56 | $ | 2.66 | ||||||||||||||||||||||||
| Diluted | $ | 6.86 | $ | 1.10 | $ | 6.48 | $ | 2.65 | ||||||||||||||||||||||||
| Basic, excluding non-GAAP adjustments | $ | 3.14 | $ | 2.45 | $ | 8.25 | $ | 7.92 | ||||||||||||||||||||||||
| Diluted, excluding non-GAAP adjustments | $ | 3.09 | $ | 2.43 | $ | 8.14 | $ | 7.89 | ||||||||||||||||||||||||
(1) | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | |||||||||||||||||||||||||||||||
(2) | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. | |||||||||||||||||||||||||||||||
(3) | The amount included in the nine month period ended September 26, 2026 primarily reflects a $181.7 million loss on the CDMO and Cell Solutions Divestiture, net with a $1.4 million gain on the European Discovery Divestiture. The amount included in 2025 relates to a gain on the sale of a DSA site. | |||||||||||||||||||||||||||||||
(4) | Represents non-cash interest expense recognized from the accretion of deferred purchase consideration associated with the Cambodia NHP Supplier acquisition. | |||||||||||||||||||||||||||||||
(5) | The amount included in the nine month period ended September 26, 2026 reflects the tax benefit resulting from the reversal of an unrecognized tax benefit reserve following newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction. | |||||||||||||||||||||||||||||||
12
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | |||||||||||||||||||||||||||||
| SCHEDULE 6 | |||||||||||||||||||||||||||||
| RECONCILIATION OF GAAP REVENUE GROWTH | |||||||||||||||||||||||||||||
TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED) (1) | |||||||||||||||||||||||||||||
| Three Months Ended September 26, 2026 | Total CRL | DSA Segment | MS Segment | RMS Segment | |||||||||||||||||||||||||
| Revenue growth, reported | (2.2) | % | (0.7) | % | (6.2) | % | (2.8) | % | |||||||||||||||||||||
| (Increase) decrease due to foreign exchange | — | % | 0.2 | % | 0.2 | % | (0.7) | % | |||||||||||||||||||||
Contribution from acquisitions (2) | (0.2) | % | — | % | (0.8) | % | — | % | |||||||||||||||||||||
Impact of divestitures (3) | 7.1 | % | 6.4 | % | 14.2 | % | 2.9 | % | |||||||||||||||||||||
Non-GAAP revenue growth, organic (4) | 4.7 | % | 5.9 | % | 7.4 | % | (0.6) | % | |||||||||||||||||||||
| Nine Months Ended September 26, 2026 | Total CRL | DSA Segment | MS Segment | RMS Segment | |||||||||||||||||||||||||
| Revenue growth, reported | (1.3) | % | (0.6) | % | (2.2) | % | (2.3) | % | |||||||||||||||||||||
| (Increase) decrease due to foreign exchange | (1.1) | % | (0.8) | % | (1.5) | % | (1.8) | % | |||||||||||||||||||||
Contribution from acquisitions (2) | (0.1) | % | — | % | (0.6) | % | — | % | |||||||||||||||||||||
Impact of divestitures (3) | 3.5 | % | 2.9 | % | 8.1 | % | 1.6 | % | |||||||||||||||||||||
Non-GAAP revenue growth, organic (4) | 1.0 | % | 1.5 | % | 3.8 | % | (2.5) | % | |||||||||||||||||||||
(1) | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | ||||||||||||||||||||||||||||
(2) | The contribution from acquisitions reflects only completed acquisitions. | ||||||||||||||||||||||||||||
(3) | Impact of divestitures relates to the sale of certain European Discovery Services businesses in May 2026 within the DSA reportable segment as well as the sale of the CDMO and Cell Solutions businesses in May 2026 within the Manufacturing reportable segment and RMS reportable segment, respectively. | ||||||||||||||||||||||||||||
(4) | Organic revenue growth is defined as reported revenue growth adjusted for acquisitions, divestitures and foreign exchange. | ||||||||||||||||||||||||||||
13